The successful clinical use of monoclonal antibodies is one of the most significant advances in cancer treatment today. Antibody-based therapies provide desirable attractive specificity, multiple mechanisms of action, and desirable safety profiles. Humanization, optimization for drug-like properties, and cloning antibody genes for expression in large quantities are labor-intensive processes requiring specialized equipment and expertise that challenge the translation of basic research to the discovery of drug candidates.
The CPRIT (Cancer Prevention Research Institute of Texas) Therapeutic Monoclonal Antibody Discovery and Development Core Facility aims to provide state-wide support and service to advance lead antibodies from academic laboratories to the stage of preclinical development. Core service is divided into four modules, four drug modalities and performed by a team with diverse and complementary knowledge and expertise.
Major functional modules:
- Lead identification;
- Lead optimization;
- Lead construction; and
- Antibody production.
Major drug modalities:
- Monoclonal antibodies (mAbs);
- Antibody-drug conjugates (ADCs);
- Bispecific antibodies (BsAbs); and
- Chimeric antigen receptor T-cells (CAR-T)